113 related articles for article (PubMed ID: 2917019)
1. Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells.
Aboud-Pirak E; Lesur B; Rao KS; Baurain R; Trouet A; Schneider YJ
Biochem Pharmacol; 1989 Feb; 38(4):641-8. PubMed ID: 2917019
[TBL] [Abstract][Full Text] [Related]
2. Binding and endocytosis of a monoclonal antibody to a high molecular weight human milk fat globule membrane-associated antigen by cultured MCF-7 breast carcinoma cells.
Aboud-Pirak E; Sergent T; Otte-Slachmuylder C; Abarca J; Trouet A; Schneider YJ
Cancer Res; 1988 Jun; 48(11):3188-96. PubMed ID: 3365702
[TBL] [Abstract][Full Text] [Related]
3. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
Trouet A; Masquelier M; Baurain R; Deprez-De Campeneere D
Proc Natl Acad Sci U S A; 1982 Jan; 79(2):626-9. PubMed ID: 6952214
[TBL] [Abstract][Full Text] [Related]
4. Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.
Sweet F; Rosik LO; Sommers GM; Collins JL
Gynecol Oncol; 1989 Sep; 34(3):305-11. PubMed ID: 2788601
[TBL] [Abstract][Full Text] [Related]
5. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
Dillman RO; Johnson DE; Shawler DL; Koziol JA
Cancer Res; 1988 Nov; 48(21):6097-102. PubMed ID: 3262420
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Biddle WC; Haruta Y; Seon BK; Henderson ES; Sarcione EJ
Leuk Res; 1989; 13(8):699-707. PubMed ID: 2529399
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2.
Li S; Zhang XY; Qiao TD; Chen XT; Zhang SY; Chen LJ
Oncol Res; 1992; 4(11-12):447-53. PubMed ID: 1299375
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
Sinkule JA; Rosen ST; Radosevich JA
Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of doxorubicin-monoclonal antibody conjugate on human bladder cancer.
Yu DS; Chu TM; Yeh MY; Chang SY; Ma CP; Han SH
J Urol; 1988 Aug; 140(2):415-21. PubMed ID: 3398165
[TBL] [Abstract][Full Text] [Related]
10. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
Dillman RO; Johnson DE; Ogden J; Beidler D
Mol Biother; 1989; 1(5):250-5. PubMed ID: 2515870
[TBL] [Abstract][Full Text] [Related]
11. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
Embleton MJ; Rowland GF; Simmonds RG; Jacobs E; Marsden CH; Baldwin RW
Br J Cancer; 1983 Jan; 47(1):43-9. PubMed ID: 6571783
[TBL] [Abstract][Full Text] [Related]
12. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.
Lavie E; Hirschberg DL; Schreiber G; Thor K; Hill L; Hellstrom I; Hellstrom KE
Cancer Immunol Immunother; 1991; 33(4):223-30. PubMed ID: 2059966
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and specificity of vindesine monoclonal anti-carcinoembryonic antigen conjugate with nine human cancer cell lines.
Ford CH; Bartlett SE; Casson AG; Marsden CH; Gallant ME
NCI Monogr; 1987; (3):107-16. PubMed ID: 3547144
[TBL] [Abstract][Full Text] [Related]
15. Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity.
Gallego J; Price MR; Baldwin RW
Int J Cancer; 1984 Jun; 33(6):737-44. PubMed ID: 6376376
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.
Durrant LG; Garnett MC; Gallego J; Armitage NC; Ballantyne KC; Marksman RA; Hardcastle JD; Baldwin RW
Br J Cancer; 1987 Dec; 56(6):722-6. PubMed ID: 3435698
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and selectivity of vindesine monoclonal anti-carcinoembryonic antigen antibody conjugates on human tumor cell lines grown as xenografts in nude mice.
Casson AG; Ford CH; Marsden CH; Gallant ME; Bartlett SE
NCI Monogr; 1987; (3):117-24. PubMed ID: 3821911
[TBL] [Abstract][Full Text] [Related]
18. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
19. Tumor reactive cis-aconitylated monoclonal antibodies coupled to daunorubicin through a peptide spacer are unable to kill tumor cells.
Law KL; Studtmann KE; Carlson RE; Swanson TA; Buirge AW; Ahmad A
Anticancer Res; 1990; 10(3):845-52. PubMed ID: 2369098
[TBL] [Abstract][Full Text] [Related]
20. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
Deguchi T; Chu TM; Leong SS; Horoszewicz JS; Lee CL
Cancer Res; 1986 Aug; 46(8):3751-5. PubMed ID: 3731053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
